GlassScriptPhysician profile
Evan A King
NPI 1164018537
$1,031.22
in general payments reported to CMS, 2019-2025
14 companies · $282 in 2025
The $282 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $35.13 · 2022: $140 · 2023: $433 · 2024: $141 · 2025: $282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $856.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $855.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $194.44 | 2022-2024 | Cardiomems |
| E.R. Squibb & Sons, L.L.C. | $182.73 | 2022-2023 | Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $154.12 | 2025 | Lifevest |
| Abiomed | $137.56 | 2023-2025 | Impella |
| Atricure, INC. | $115.86 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $63.43 | 2022-2024 | Uptravi |
| Scpharmaceuticals INC. | $34.38 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $26.64 | 2021-2023 | Farxiga |
| Aurinia Pharma U.S., INC. | $24.86 | 2024 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $23.82 | 2022 | |
| Novartis Pharmaceuticals Corporation | $23.45 | 2023 | |
| Amgen INC. | $21.96 | 2021 | |
| Novo Nordisk INC | $15.04 | 2024 | Ozempic |
| Pfizer INC. | $12.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.